Tissue biology research
BPC-157 Dosage, Protocol & Research Guide
- MW 1,419.5 g/mol
- CAS 137525-51-0
Dose overview
Every range below is taken from the cited source and carries its evidence grade.
Human data and community reports
| Source | Population | Dose | Frequency | Route | Duration | Evidence |
|---|---|---|---|---|---|---|
| IRB-approved pilot study in 2 adults (Altern Ther Health Med 2025)[2] | human2 adults (a 58-year-old man and a 68-year-old woman, each with prior intravenous BPC-157), IRB-approved pilot at a private clinic in Florida | 10 mg[2]intravenous, day 1 infusion, 10 mg in 250 mL normal saline over one hour | one infusion, day 1 | intravenous | — | Human clinical trialStudy details from the source: IRB-approved pilot study in 2 adults (Altern Ther Health Med 2025): intravenous BPC-157 10 mg in 250 mL normal saline infused over one hour on day 1 (the day 2 infusion was 20 mg; see the next row) |
| Same IRB-approved pilot study in 2 adults (Altern Ther Health Med 2025)[2] | human2 adults (a 58-year-old man and a 68-year-old woman, each with prior intravenous BPC-157), IRB-approved pilot at a private clinic in Florida | 20 mg[2]intravenous, day 2 infusion, 20 mg in 250 mL normal saline over one hour | one infusion, day 2 | intravenous | — | Human clinical trialStudy details from the source: Same IRB-approved pilot study in 2 adults (Altern Ther Health Med 2025): intravenous BPC-157 20 mg in 250 mL normal saline infused over one hour on day 2 (the day 1 infusion was 10 mg; see the previous row) |
| Human review or observational report[3] | human12 women aged 39 to 76 (mean 58.3) who had not responded to pentosan polysulfate, one private clinic | 10 mg[3]intravesical injection (cystoscopy); total 10 mg in one procedure | single procedure | other | — | Human review or observational reportStudy details from the source: Pilot report in 12 women with moderate to severe interstitial cystitis (Altern Ther Health Med 2024; a 2026 systematic review describes it as a retrospective pilot): BPC-157 (503A pharmacy compounded) 10 mg total injected around the area of bladder inflammation during one cystoscopy |
Evidence grades: A approved label, B human trial, C observational, D animal study, E community-reported.
Reconstitution calculator
Calculator example, not a recommended amount
- Concentration
- 2.5 mg/mL
- Volume to draw
- 0.1 mL
- Units on a U-100 syringe
- 10 units
Properties
- CAS
- 137525-51-0
- Molecular weight
- 1,419.5 g/mol
- Formula
- Not yet recorded
- Sequence
- GEPPPGKPADDAGLV
- Aliases
- Body Protection Compound-157, Pentadecapeptide BPC 157, PL-14736, Bepecin
- Vial sizes (mg)
- 5, 10
Storage notes
- Lyophilized
- Not yet recorded from a cited source
- Reconstituted stability (days)
- Not yet recorded from a cited source
Side effects, contraindications and regulatory status
Reported side effects
- Pilot study, 2 adults given intravenous BPC-157 (10 mg day 1, 20 mg day 2): no measurable effects on the tested heart, liver, kidney, thyroid or glucose biomarkers and the authors report no participant-reported side effects; they say future studies are needed (Altern Ther Health Med 2025).[2] Human trial
- Retrospective chart review, 16 people with knee pain contacted by phone after intra-articular BPC 157 (alone or with thymosin beta 4); the abstract reports no adverse-event data (Altern Ther Health Med 2021).[5] Observational
- Pilot report, 12 women given BPC-157 10 mg by injection around the bladder inflammation area in one cystoscopy procedure: no adverse events reported; uncontrolled, one private clinic (Altern Ther Health Med 2024).[3] Observational
- Systematic review (Acta Orthop Belg 2026): 3 human studies found (n=30); all reported no adverse events related to the intervention, but the studies were judged poor quality and certainty of evidence very low.[6] Observational
- Systematic review (HSS J 2025): 36 studies, 35 preclinical and 1 clinical; the authors state no clinical safety data were found and that adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety.[7] Observational
- Same review (HSS J 2025): in preclinical safety studies (animal studies, not human) the authors report no adverse effects across several organ systems.[7] Animal study
- FDA safety-risk page (current as of 2026-04-22): compounded drugs containing BPC-157 may pose risk for immunogenicity, with peptide-related impurity and characterization complexity; FDA found no or only limited safety information for the proposed routes.[1] Regulator or expert-panel statement
Cautions from reviews and trials
- Review cautions: a 2026 systematic review concludes BPC-157 should not be used clinically in humans outside ethically approved, regulated, high-quality clinical trials (Acta Orthop Belg).[6] Observational
Regulatory status
Listed in the 'nominated but withdrawn' table of the FDA bulk-substance safety-risk page (content current 2026-04-22). Checked 2026-10-20.[1] Source
Report any adverse reaction to a qualified healthcare professional.
What the research says
Summaries of the cited studies, each with its evidence grade.
IRB-approved pilot study in 2 adults (Altern Ther Health Med 2025)[2]
IRB-approved pilot study in 2 adults (Altern Ther Health Med 2025): intravenous BPC-157 10 mg in 250 mL normal saline infused over one hour on day 1 (the day 2 infusion was 20 mg; see the next row)
pubmed.ncbi.nlm.nih.gov[3]
Pilot report in 12 women with moderate to severe interstitial cystitis (Altern Ther Health Med 2024; a 2026 systematic review describes it as a retrospective pilot): BPC-157 (503A pharmacy compounded) 10 mg total injected around the area of bladder inflammation during one cystoscopy
Unilateral adrenalectomy study (Pharmaceuticals 2026, doi 10.3390/ph19060873)[4]
Unilateral adrenalectomy study (Pharmaceuticals 2026, doi 10.3390/ph19060873): rats given BPC 157 10 µg/kg or 10 ng/kg intragastrically 5 minutes after adrenalectomy versus saline 5 mL/kg
Compare vial sizes
| Size | Price | Doses available from the vial Calculated | Cost per dose Calculated |
|---|---|---|---|
| 10 mg | $58.99 | — | — |
Cost per dose uses the listed partner price and the reference dose cited on this page. Prices change; check the product page.
Calculated from a default of 2 mL water (adjustable).
PeptideCheck may earn a commission when you use Pepcore links, at no extra cost to you. Read the disclosure.
Frequently asked questions
What dose figures are published for BPC-157?
Cited figures on this page: 10 mg one infusion, day 1, intravenous, day 1 infusion, 10 mg in 250 mL normal saline over one hour [2] (Human clinical trial, evidence grade B); 20 mg one infusion, day 2, intravenous, day 2 infusion, 20 mg in 250 mL normal saline over one hour [2] (Human clinical trial, evidence grade B); 10 mg single procedure, intravesical injection (cystoscopy); total 10 mg in one procedure [3] (Human review or observational report, evidence grade C). These are summaries of published sources, not medical advice. Each figure links to its source in the references.
What is the regulatory status of BPC-157?
Listed in the 'nominated but withdrawn' table of the FDA bulk-substance safety-risk page (content current 2026-04-22). Checked 2026-10-20.
Compound facts
What is the molecular weight of BPC-157?
What is the CAS number of BPC-157?
How is BPC-157 stored in the laboratory?
References
Numbered sources used on this page. Markers in the text link here.
- fda.gov Regulator or expert-panel statement
- IRB-approved pilot study in 2 adults (Altern Ther Health Med 2025) pubmed.ncbi.nlm.nih.gov Human trial
- pubmed.ncbi.nlm.nih.gov Observational
- Unilateral adrenalectomy study (Pharmaceuticals 2026, doi 10.3390/ph19060873) pmc.ncbi.nlm.nih.gov Animal study
- pubmed.ncbi.nlm.nih.gov Observational
- pubmed.ncbi.nlm.nih.gov Observational
- pubmed.ncbi.nlm.nih.gov Observational
Vial sizes and protocols
10 mgPartner size
Available from Pepcore
Supplied as research material for laboratory use only.
- Shop at PepcoreCoupon code
LAUNCH20
PeptideCheck may earn a commission when you use Pepcore links, at no extra cost to you. Read the disclosure.